3年长期替比夫定治疗,疗效和安全性

StephenW

<http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2011.02490.x/abstract>

Efficacy and safety of prolonged 3-year telbivudine treatment in patients
with chronic hepatitis B

Edward J. Gane1, Yuming Wang2, Yun-Fan Liaw3, JinLin Hou4, Satawat
Thongsawat5, MoBin Wan6, Young M. Moon7, JiDong Jia8, You C. Chao9, Junqi
Niu10, Nancy Leung11, Didier Samuel12, Chao Wei Hsu13, Weibin Bao14,
Patricia Lopez15, Claudio Avila15

Article first published online: 16 MAR 2011
DOI: 10.1111/j.1478-3231.2011.02490.x
© 2011 John Wiley & Sons A/S
Issue

Liver International
Volume 31, Issue 5, pages 676–684, May 2011

Abstract

Background: In the GLOBE trial, telbivudine demonstrated superior efficacy
to lamivudine at 2 years in patients with chronic hepatitis B (CHB).

Aims: To investigate the long-term efficacy and safety of telbivudine in
the telbivudine-treated cohort from the GLOBE trial.

Methods: Virological and biochemical responses were assessed in 213
HBeAg-positive and 186 HBeAg-negative CHB patients who continued
telbivudine treatment for 3 years.

Results: Undetectable hepatitis B virus DNA and HBeAg seroconversions were
achieved by 77 and 37% of HBeAg-positive patients respectively. Cumulative
HBeAg seroconversion rate was 46%. HBeAg seroconversion was sustained at 52
weeks off therapy in 84% of the patients enrolled in the off-treatment
follow-up arm of the study. Undetectable viraemia and normal alanine
aminotransferase (ALT) levels at 3 years were achieved by 85 and 83% of
HBeAg-negative patients respectively. Genotypic resistance rates for the
study population who continued therapy during the third year were 11.3 in
HBeAg-positive and 6.5% in HBeAg-negative patients. Patients with
undetectable viraemia at treatment week 24 had optimal outcomes at 3 years.
In the HBeAg-positive population, cumulative HBeAg seroconversion occurred
in 58%. Resistance rates for HBeAg-positive and HBeAg-negative patients
were 3.6 and 6.2% respectively. The telbivudine safety profile during
prolonged therapy was similar to that in the GLOBE trial.

Conclusions: Three years of telbivudine treatment yielded high rates of
viral suppression and ALT normalization with a favourable safety profile.
High rates of HBeAg seroconversion were achieved with prolonged telbivudine
therapy and were sustained in the majority of patients over 52 weeks off
therapy.

StephenW

长期疗效和安全性3年替比夫定治疗的患者
慢性乙型肝炎

爱德华J.加恩1，裕民Wang2，云帆Liaw3，吉林Hou4，Satawat
Thongsawat5，莫宾Wan6，杨米月亮7，冀东Jia8，你三超9，军棋
Niu10，南希Leung11，迪迪埃Samuel12，超威Hsu13，渭滨Bao14，
帕特里夏Lopez15，克劳迪奥Avila15

文章首先发表时间：2011年3月16日
分类号：10.1111/j.1478-3231.2011.02490.x
© 2011约翰Wiley＆Sons出版A / S公司
发行

国际肝病
第31卷，第5期，页676-684，2011年5月

摘要

背景：因为这世界上的审判，替比夫定显示出卓越的功效
在2年至拉米夫定对慢性乙型肝炎（CHB）患者。

目的：探讨长期疗效和安全性的替比夫定
从地球的试验替比夫定治疗的队列。

方法：病毒学和生物化学反应进行了评估213
HBeAg阳性和186 HBeAg阴性慢性乙型肝炎患者谁继续
替比夫定治疗3年。

结果：检测不到乙肝病毒DNA和e抗原seroconversions了
取得了77和37的HBeAg阳性的患者分别％。累积
HBeAg血清转换率是46％。 HBeAg血清转换是持续52
过84％的病人治疗周参加了关闭处理
后续研究的分支。检测不到病毒血症和正常丙氨酸
转氨酶（ALT）水平，3年时达到了85和83％的
e抗原阴性患者分别。耐药率的基因型
谁继续研究人口在第三年分别为11.3治疗中
e抗原阳性和6.5 HBeAg阴性患者％。患者
在治疗24周时检测不到病毒血症曾在3年的最佳结果。
在e抗原阳性人群中，累计发生HBeAg血清转换
58％。对于HBeAg阳性和HBeAg阴性患者耐药率
分别为3.6和6.2％。替比夫定期间的安全性
长期的治疗相似，因为这世界上审判。

结论：三替比夫定治疗两年后产生的高利率
病毒抑制和ALT正常化创造良好的安全性。
HBeAg血清转换率分别高达到长时间的替比夫定
治疗，并于广大患者持续52个星期的假
治疗。

maxthon

医生说替比夫定这个药不怎么好。请问楼主现在吃什么药啊？

user321

替比夫定销量好像不太好

benben00

疗效看起来是很好，但是副反应的描述似乎过于简单了吧

StephenW

benben00 发表于 2011-4-8 13:43
疗效看起来是很好，但是副反应的描述似乎过于简单了吧

你是对的. 报告没有提及副作用. 应阅读整份报告。

qiuqiu518

是药三分毒...有什么办法呢